PURPOSE: To compare the performance of self-report instruments assessing adherence to antiretroviral therapy (ART) in patients starting ART for the first time and in a predominately Hispanic population. METHODS: Of 184 patients in a prospective observational cohort study of newly diagnosed, minority patients of low socioeconomic status, 54 were given Medication Event Monitoring System (MEMS) caps for their boosted protease inhibitor (PI) or non-nucleoside reverse transcriptase inhibitor (NNRTI). They completed a 4-week recall visual analogue scale (VAS), the Adult AIDS Clinical Trial Group (AACTG) 4-day recall instrument, and a 1-month recall qualitative single-item measure every 3 months for up to 18 months in English or Spanish. Electronic pharmacy records recorded refill dates. Spearman correlation coefficients were calculated to compare self-report measures with MEMS data and pharmacy data. RESULTS: Of 46 patients with MEMS data, mean adherence was 84.7% (SD 35.6) by MEMS, 84.5% (SD 15.1) by pharmacy, 95.4% (SD 11.9) by VAS, 95.8% (SD 17.2) by AACTG, and 87.6% (SD 28.2) by qualitative single item. The correlation coefficient (CC) of VAS with MEMS was 0.37 (P < .01), and with pharmacy it was 0.34 (P < .01). The CC of the AACTG with MEMS was 0.32 (P < .01), and with pharmacy it was 0.28 (P < .01). The qualitative single item had a CC with MEMS of 0.24 (P < .01) and with pharmacy of 0.32 (P < .01). Spanish-speaking patients' VAS adherence had a CC of 0.40 (P < .01) with MEMS. CONCLUSIONS: The VAS, AACTG, and qualitative single-item measures correlated significantly with MEMS and pharmacy data. Our data support self-administration of the VAS, even in Span-ish speakers.
PURPOSE: To compare the performance of self-report instruments assessing adherence to antiretroviral therapy (ART) in patients starting ART for the first time and in a predominately Hispanic population. METHODS: Of 184 patients in a prospective observational cohort study of newly diagnosed, minority patients of low socioeconomic status, 54 were given Medication Event Monitoring System (MEMS) caps for their boosted protease inhibitor (PI) or non-nucleoside reverse transcriptase inhibitor (NNRTI). They completed a 4-week recall visual analogue scale (VAS), the Adult AIDS Clinical Trial Group (AACTG) 4-day recall instrument, and a 1-month recall qualitative single-item measure every 3 months for up to 18 months in English or Spanish. Electronic pharmacy records recorded refill dates. Spearman correlation coefficients were calculated to compare self-report measures with MEMS data and pharmacy data. RESULTS: Of 46 patients with MEMS data, mean adherence was 84.7% (SD 35.6) by MEMS, 84.5% (SD 15.1) by pharmacy, 95.4% (SD 11.9) by VAS, 95.8% (SD 17.2) by AACTG, and 87.6% (SD 28.2) by qualitative single item. The correlation coefficient (CC) of VAS with MEMS was 0.37 (P < .01), and with pharmacy it was 0.34 (P < .01). The CC of the AACTG with MEMS was 0.32 (P < .01), and with pharmacy it was 0.28 (P < .01). The qualitative single item had a CC with MEMS of 0.24 (P < .01) and with pharmacy of 0.32 (P < .01). Spanish-speaking patients' VAS adherence had a CC of 0.40 (P < .01) with MEMS. CONCLUSIONS: The VAS, AACTG, and qualitative single-item measures correlated significantly with MEMS and pharmacy data. Our data support self-administration of the VAS, even in Span-ish speakers.
Authors: J H Arnsten; P A Demas; H Farzadegan; R W Grant; M N Gourevitch; C J Chang; D Buono; H Eckholdt; A A Howard; E E Schoenbaum Journal: Clin Infect Dis Date: 2001-09-05 Impact factor: 9.079
Authors: H Liu; C E Golin; L G Miller; R D Hays; C K Beck; S Sanandaji; J Christian; T Maldonado; D Duran; A H Kaplan; N S Wenger Journal: Ann Intern Med Date: 2001-05-15 Impact factor: 25.391
Authors: Cheryl A Liechty; Christopher S Alexander; P Richard Harrigan; J David Guzman; Edwin D Charlebois; Andrew R Moss; David R Bangsberg Journal: AIDS Date: 2004-01-02 Impact factor: 4.177
Authors: D L Paterson; S Swindells; J Mohr; M Brester; E N Vergis; C Squier; M M Wagener; N Singh Journal: Ann Intern Med Date: 2000-07-04 Impact factor: 25.391
Authors: Patricia García de Olalla; Hernando Knobel; Alexia Carmona; Ana Guelar; José L López-Colomés; Joan A Caylà Journal: J Acquir Immune Defic Syndr Date: 2002-05-01 Impact factor: 3.731
Authors: Ajay K Sethi; David D Celentano; Stephen J Gange; Richard D Moore; Joel E Gallant Journal: Clin Infect Dis Date: 2003-09-19 Impact factor: 9.079
Authors: Kristi L Stringer; Bulent Turan; Lisa McCormick; Modupeoluwa Durojaiye; Laura Nyblade; Mirjam-Colette Kempf; Bronwen Lichtenstein; Janet M Turan Journal: AIDS Behav Date: 2016-01
Authors: Sarah Pollock; Forrest Toegel; August F Holtyn; Andrew M Rodewald; Jeannie-Marie Leoutsakos; Michael Fingerhood; Kenneth Silverman Journal: Drug Alcohol Depend Date: 2020-04-25 Impact factor: 4.492
Authors: Forrest Toegel; August F Holtyn; Sarah Pollock; Andrew M Rodewald; Jeannie-Marie Leoutsakos; Michael Fingerhood; Kenneth Silverman Journal: HIV Res Clin Pract Date: 2020-03-05
Authors: David B Hanna; Molly Jung; Xiaonan Xue; Kathryn Anastos; Jennifer M Cocohoba; Mardge H Cohen; Elizabeth T Golub; Nancy A Hessol; Alexandra M Levine; Tracey E Wilson; Mary A Young; Robert C Kaplan Journal: AIDS Patient Care STDS Date: 2016-10 Impact factor: 5.078
Authors: David B Hanna; Nancy A Hessol; Elizabeth T Golub; Jennifer M Cocohoba; Mardge H Cohen; Alexandra M Levine; Tracey E Wilson; Mary Young; Kathryn Anastos; Robert C Kaplan Journal: J Acquir Immune Defic Syndr Date: 2014-04-15 Impact factor: 3.731
Authors: Robert H Remien; Curtis Dolezal; Glenn J Wagner; Kathy Goggin; Ira B Wilson; Robert Gross; Marc I Rosen; Jie Shen; Jane M Simoni; Carol E Golin; Julia H Arnsten; David R Bangsberg; Honghu Liu Journal: AIDS Behav Date: 2014-08
Authors: Yuehan Zhang; Tracey E Wilson; Adebola Adedimeji; Daniel Merenstein; Joel Milam; Jennifer Cohen; Mardge Cohen; Elizabeth T Golub Journal: AIDS Behav Date: 2018-03